JUNS JUPITER NEUROSCIENCES, INC.

Nasdaq jupiterneurosciences.com


$ 1.42 $ 0.05 (3.62 %)    

Friday, 31-Oct-2025 15:59:51 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.43
$ 1.41
$ 1.36 x 970
$ 1.47 x 20
$ 1.36 - $ 1.46
$ 0.51 - $ 19.51
97,266
na
47.45M
$ -0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-18-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 12-23-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jupiter-neurosciences-launches-nugevia-mnd-to-boost-cognitive-health-using-resveratrol-and-novasol-curcumin

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuropro...

 jupiter-neurosciences-highlights-jotrol

JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in ...

 jupiter-neurosciences-unveils-nugevia-pwr-to-meet-demand-for-clinically-validated-longevity-supplements-commercial-availability-expected-in-fall-2025

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfo...

 jupiter-neurosciences-commercially-launches-nugevia-first-consumer-products-roll-out-in-q3-2025

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's ev...

 jupiter-neurosciences-highlights-upcoming-milestones-in-shareholder-letter-including-lead-clinical-asset-jotrol-into-a-phase-2a-clinical-trial-in-parkinsons-disease

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION